Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
227.79
+2.45 (1.09%)
At close: Apr 28, 2026, 4:00 PM EDT
227.23
-0.56 (-0.25%)
After-hours: Apr 28, 2026, 4:42 PM EDT
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $23.99B in the quarter ending September 28, 2025, with 6.77% growth. This brings the company's revenue in the last twelve months to $92.15B, up 5.08% year-over-year. In the year 2024, Johnson & Johnson had annual revenue of $88.82B with 4.30% growth.
Revenue (ttm)
$92.15B
Revenue Growth
+5.08%
P/S Ratio
5.67
Revenue / Employee
$697,265
Employees
138,200
Market Cap
548.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
| Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
| Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
| Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
| Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
| Dec 29, 2019 | Pro | Pro | Pro |
| Dec 30, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Jan 1, 2017 | Pro | Pro | Pro |
| Jan 3, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Eli Lilly and Company | 65.18B |
| Merck & Co. | 65.01B |
| Pfizer | 62.58B |
| AbbVie | 61.16B |
| AstraZeneca | 58.74B |
| Novartis AG | 56.67B |
| Sanofi | 54.85B |
| Novo Nordisk | 48.59B |
JNJ News
- 1 day ago - Johnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions Conference - Business Wire
- 1 day ago - J&J sees AI halving the time to generate drug development leads - Reuters
- 1 day ago - FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA) - PRNewsWire
- 4 days ago - Johnson & Johnson to launch on TrumpRx with four of its prescription drugs, CBS News reports - Reuters
- 4 days ago - Cramer says look to these 4 stocks to go with your high-flying tech names - CNBC
- 5 days ago - Johnson & Johnson Transcript: AGM 2026 - Transcripts
- 6 days ago - IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG) - PRNewsWire
- 6 days ago - Johnson & Johnson Announces CE Mark Approval for the New ETHICON™ 4000 Stapler - Business Wire